Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / KLK2

KLK2

Basics

Aliases:
This biomarker is also known as:
  • glandular kallikrein 2,
  • KLK2A2,
  • hK2,
  • Tissue kallikrein-2,
  • kallikrein 2, prostatic,
  • hGK-1,
  • MGC12201,
  • Kallikrein-2,
  • Glandular kallikrein-1,
  • kallikrein-related peptidase 2,

View in BioMuta

Description…

The glandular kallikreins are a distinct group of serine proteases with molecular masses of 25,000 to 40,000. The glandular kallikrein gene family comprises 25 to 30 highly homologous genes that encode specific proteases involved in the processing of biologically active peptides (they cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin). Several human kallikrein genes have been isolated.

Attributes

QA State: Accepted
Type: Protein
Short Name:
HGNC Name: KLK2

Organs

The following organs have data associated with this biomarker…

Prostate

Attributes

Phase: Two
QA State: Accepted

Overview

Human glandular kallikrein (hK2) has been shown to add important information regarding the early detection and staging of prostate cancer. Together with percent free PSA (%fPSA), hK2 may help to distinguish preoperatively between pT2 and pT3 prostate cancer.

Performance Comment

hK2, hK4 and hK11 do not distinguish cases from controls in these populations.

Supporting Study Data

The following studies/protocols provide evidence supporting KLK2 indications for the Prostate…

Prostate Rapid Pre-Validation Set

Determine which markers move to validation using the prospectie prostate reference set samples.

View more about this study
Biomarker Characteristics Summary

No statistics found.

Decision Rule

No clinically useful decision rule found.

Additional Study-Specific Protocols
Study-Specific Publications

No study-specific publications defined.

Study-Specific Resources

No study-specific resources defined.

Prostate Rapid Reference Set Applicant: Diamandis - Mt Sinai (2006)

No abstract available.

View more about this study
Biomarker Characteristics Summary
Notes Sensitivity Specificity Prevalence NPV PPV Specific Assay Type
Measured among 123 samples (60 controls and 63 cases). Among the cases, 33 had low Gleason grade (<7) and 30 had high Gleason grade (>=7). When comparing cases with Gleason grade >=7 (n=30) to the pool of controls and cases with Gleason grade <7 (n=93), the AUC was 0.63 (0.52, 0.75). No specific cutoff was preselected for this analysis. N/A N/A N/A N/A N/A
Measured among 123 samples (60 controls and 63 cases). Among the cases, 33 had low Gleason grade (<7) and 30 had high Gleason grade (>=7). When comparing all cases (low and high Gleason grade) to controls, the AUC was 0.59 (0.48, 0.69). No specific cutoff was preselected for this analysis. N/A N/A N/A N/A N/A
Decision Rule

No clinically useful decision rule found.

Additional Study-Specific Protocols
Study-Specific Publications

No study-specific publications defined.

Study-Specific Resources

No study-specific resources defined.

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

No organ-specific publications defined.

Organ-Specific Resources

No organ-specific resources defined.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.